AbbVie ups profit outlook, BMS lowers forecast as sales dip

Outside of Humira revenue declines, AbbVie reported that both Skyrizi and Rinvoq experienced exceptional growth, with global revenues increasing 50.4% and 55.1% over the same period.

Related Keywords

Richarda Gonzalez ,Giovanni Caforio ,Pomalyst Revlimid ,Christopher Boener ,Bristol Myers Squibb ,Takeda Pharmaceuticals ,Munich Based Tubulius ,